Robert Hazlett
Stock Analyst at BTIG
(1.29)
# 3,637
Out of 5,005 analysts
23
Total ratings
39.13%
Success rate
-1.36%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $6.05 | +296.69% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $60 | $60.55 | -0.91% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $0.51 | +2,672.28% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $1,200 → $1,000 | $7.00 | +14,185.71% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $120.30 | -18.54% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $8.70 | +589.66% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $6.43 | +879.78% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $9.92 | +192.34% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $1.90 | +1,368,321.05% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $2.83 | +112.01% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $11.85 | +51.90% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $6.05
Upside: +296.69%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $60
Current: $60.55
Upside: -0.91%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $0.51
Upside: +2,672.28%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $1,200 → $1,000
Current: $7.00
Upside: +14,185.71%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $120.30
Upside: -18.54%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $8.70
Upside: +589.66%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $6.43
Upside: +879.78%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $9.92
Upside: +192.34%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $1.90
Upside: +1,368,321.05%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $2.83
Upside: +112.01%
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $11.85
Upside: +51.90%